MedTrace Logo

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

NCT00537511 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2019-11-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the maximum tolerated dose and safety of CC-4047 (pomalidomide) given in combination with cisplatin and etoposide in patients with extensive disease small cell lung cancer.

Conditions

  • Carcinoma, Small Cell

Interventions

DRUG

Pomalidomide

DRUG

Cisplatin

DRUG

Etoposide

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Ulf Jungnelius, MD · Celgene Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-01
Primary Completion
2010-11-01
Completion
2010-12-01

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00537511 on ClinicalTrials.gov